Purpose: Metformin combined with the mTOR inhibitor rapamycin showed potential synergistic anti-tumor activity in preclinical studies in pancreatic ductal adenocarcinoma (PDA). The gene discussed is MTOR; the disease is pancreatic ductal adenocarcinoma.